@article{7a9fe002786c4f7ba81003e3430d8b4f,
title = "Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma{\textregistered}) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)",
abstract = "We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma{\textregistered}, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.",
keywords = "Clinical trial, HER2 positive, Metastatic breast cancer, Trastuzumab biosimilar, ctDNA",
author = "Sim, {Sung Hoon} and Kim, {Jeong Eun} and Kim, {Min Hwan} and Park, {Yeon Hee} and Kim, {Jee Hyun} and Suh, {Koung Jin} and Koh, {Su Jin} and Park, {Kyong Hwa} and Kang, {Myoung Joo} and Ahn, {Mi Sun} and Lee, {Kyoung Eun} and Kim, {Hee Jun} and Ahn, {Hee Kyung} and Kim, {Han Jo} and Park, {Keon Uk} and Byun, {Jae Ho} and Park, {Jin Hyun} and Lee, {Gyeong Won} and Lee, {Keun Seok} and Joohyuk Sohn and Jung, {Kyung Hae} and Park, {In Hae}",
note = "Funding Information: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare , Republic of Korea (grant number: HI17C2206 ) and the National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HA22C0012 ). Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = oct,
doi = "10.1016/j.breast.2022.08.002",
language = "English",
volume = "65",
pages = "172--178",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
}